Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Feb 5;19(2):465. doi: 10.3390/ijms19020465

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Prediction of prognosis using plasma TSG-6 levels at onset of CAD. Among 135 patients with acute coronary syndrome, 32 patients had major adverse cardiovascular events (MACE) including cardiovascular death, heart failure, acute myocardial infarction, post-infarction angina, and ischemic stroke during a period of four years after onset. The follow-up period was 50.0 ± 0.57 months. (A) Plasma TSG-6 levels tended to increase in CAD patients with MACE compared with those without MACE. Data are presented as mean ± SEM. Unpaired Student’s t test was used for statistical analysis. p = 0.6109; (B) Prevalence rate of MACE (+) was significantly higher in CAD patients with TSG-6 ≥ 19 ng/mL (40%, 10/25 cases) than those with TSG-6 < 19 ng/mL (20%, 22/110 cases). Chi-squared test was used for statistical analysis. * p = 0.0338. These results are unpublished data from our follow-up study based on our previous report [10].